<DOC>
	<DOCNO>NCT02600468</DOCNO>
	<brief_summary>The purpose study collect information safety , especially serious infection malignancy , efficacy long-term use ORENCIA Intravenous Infusion 250mg patient rheumatoid arthritis .</brief_summary>
	<brief_title>Survey Long-Term Use ORENCIAÂ® Intravenous Infusion 250mg</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients begin receive treatment ORENCIA Intravenous Infusion 250mg approve indication , dosage , administration Have available HAQ data Have available DAS28ESR DAS28 CRP data Have past present history malignancy Are expect follow 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>